• Latest
  • Trending
  • All
  • News
  • Business
  • Lifestyle
Two Generic Drugs Being Tested in U.S. in Race to Find Coronavirus Treatments

Two Generic Drugs Being Tested in U.S. in Race to Find Coronavirus Treatments

March 19, 2020
Lefty Groups Biden Showered In Taxpayer Cash Coaching Illegals To Evade ICE

Lefty Groups Biden Showered In Taxpayer Cash Coaching Illegals To Evade ICE

July 14, 2025
Senate Confirms Trump’s First Judicial Pick To Replace Obama Appointee

Senate Confirms Trump’s First Judicial Pick To Replace Obama Appointee

July 14, 2025
‘Am I Going To Lose My F***ing Rights?’: Shawn Ryan Tells Newsom How Gun Laws Can Hurt Combat Vets

‘Am I Going To Lose My F***ing Rights?’: Shawn Ryan Tells Newsom How Gun Laws Can Hurt Combat Vets

July 14, 2025
‘In It To Win It’: Andrew Cuomo To Stay In NYC Mayor Race Despite Primary Defeat

‘In It To Win It’: Andrew Cuomo To Stay In NYC Mayor Race Despite Primary Defeat

July 14, 2025
Mike Johnson Tells Senate To Think Twice Before Weakening $9.4 Billion Rescissions Package

Mike Johnson Tells Senate To Think Twice Before Weakening $9.4 Billion Rescissions Package

July 14, 2025
DOJ Fires 20 Employees Who Worked With Jack Smith On Trump Prosecutions

DOJ Fires 20 Employees Who Worked With Jack Smith On Trump Prosecutions

July 14, 2025
Liberals Marked Anniversary Of Trump Shooting By Pushing Wild Conspiracies On Their Favorite Platform

Liberals Marked Anniversary Of Trump Shooting By Pushing Wild Conspiracies On Their Favorite Platform

July 14, 2025
Supreme Court Lets Trump Admin Move Forward With Slashing Education Department Staff

Supreme Court Lets Trump Admin Move Forward With Slashing Education Department Staff

July 14, 2025
‘It’s Madness!’: Mark Halperin Slams NYT For Leaving Out Key Voices In Biden Autopen Story

‘It’s Madness!’: Mark Halperin Slams NYT For Leaving Out Key Voices In Biden Autopen Story

July 14, 2025
Pro-Democrat Group Raising Cash To Stalk ICE  As Violence Against Agents Skyrockets

Pro-Democrat Group Raising Cash To Stalk ICE As Violence Against Agents Skyrockets

July 14, 2025
Corporate Media Network Completely Omits Key Detail About ICE Marijuana Farm Raid

Corporate Media Network Completely Omits Key Detail About ICE Marijuana Farm Raid

July 14, 2025
JASON ISAAC: Left Exploits Personal Tragedy In Bid To Seize Climate Policy

JASON ISAAC: Left Exploits Personal Tragedy In Bid To Seize Climate Policy

July 14, 2025
  • Donald Trump
  • State of the Union
  • Elon Musk
  • Tariffs
  • Congress
  • Faith
  • Immigration
Monday, July 14, 2025
  • Login
IJR
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Polls
No Result
View All Result
IJR
No Result
View All Result
Home News

Two Generic Drugs Being Tested in U.S. in Race to Find Coronavirus Treatments

by Reuters
March 19, 2020 at 7:24 am
in News
237 15
0
Two Generic Drugs Being Tested in U.S. in Race to Find Coronavirus Treatments

Eduardo Munoz/File Photo/Reuters

491
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

U.S. researchers, following the lead of scientists in other countries, have launched studies to see whether widely-available, low-cost generic drugs can be used to help treat the illness caused by the new coronavirus.

There are currently no vaccines or treatments for the highly-contagious COVID-19 respiratory illness, so patients can only receive supportive care for now.

But a 1,500-person trial, led by the University of Minnesota, began this week to see whether malaria treatment hydroxychloroquine can prevent or reduce the severity of COVID-19. Two other trials are studying the blood pressure drug losartan as a possible treatment for the disease.

The malaria drug, also being tested in China, Australia and France, was touted earlier this week by Tesla <TSLA.O> Chief Executive Elon Musk, who recovered from malaria in 2000 after taking the medication.

Besides having a direct antiviral effect, hydroxychloroquine suppresses the production and release of proteins involved in the inflammatory complications of several viral diseases.

“We are trying to leverage the science to see if we can do something in addition to minimizing contacts,” said Dr. Jakub Tolar, dean of the University of Minnesota Medical School and vice president for clinical affairs. “Results are likely in weeks, not months.”

Most people infected with the new coronavirus develop only mild flu-like symptoms, but around 20 percent can have more severe disease that can lead to pneumonia requiring hospitalization.

The fast-spreading virus, which emerged in China in December and is now in more than 150 countries, has infected more than 214,000 and killed over 8,700 people worldwide, including at least 145 in the United States. Experts say it could take a year or more to have a preventive vaccine ready, so effective treatments are desperately needed.

A French team on Tuesday said initial results from a 24-patient trial of hydroxychloroquine showed that 25% of patients given the drug still carried the coronavirus after six days, compared with 90% of patients given a placebo.

Tolar said he bought 1,500 doses of hydroxychloroquine for a “laughable” amount of money. “We don’t need a multibillion-dollar investment. It is part of the beauty of this approach,” he said.

But he and others cautioned that people should not be using any prescription drugs without medical oversight.

“These treatments should be used only in hospitals by critical care specialists,” said Dr. Russel Buhr, critical care pulmonologist at the University of California, Los Angeles.

Also this week, the University of Minnesota launched two trials testing losartan – one to measure whether the hypertension drug reduces the risk of organ failure for COVID-19 patients who have been hospitalized, and another looking at whether the drug can limit the need for hospitalizations.

Losartan is an angiotensin receptor 1 (AT1R) blocker, which researchers say could play a role in blocking an enzyme used by the virus to bind to cells.

Pharmaceutical companies are also working to develop treatments for COVID-19, including Gilead Sciences Inc’s <GILD.O> experimental antiviral drug remdesivir, which is given to hospitalized patients via intravenous infusion over several days.

The New England Journal of Medicine earlier this month described how the drug was successfully used on the first patient infected by the novel coronavirus in the United States.

Results from a remdesivir trial in China could come early next month, while Gilead has begun two international trials of the drug that previously failed as a potential Ebola treatment. And the National Institutes of Health last month began testing it on patients in a U.S. trial.

“We are focusing on high risk patients,” said Dr. Andre Kalil, infectious disease specialist at the University of Nebraska Medical Center and the U.S. trial’s lead investigator. “Our hope is that remdesivir will show that patients will be improving faster.”

Companies including Regeneron Pharmaceuticals Inc <REGN.O>, Eli Lilly and Co <LLY.N> and Takeda Pharmaceutical Co <4502.T> have begun to develop coronavirus treatment candidates, but human testing of their drugs has not yet started.

Anti-inflammatory drugs, like Regeneron’s Kevzara and Roche Holding AG’s <ROG.S> Actemra, have been used to treat the lung inflammation caused by COVID-19.

But in a disappointment, Chinese investigators reported this week that Kaletra, a combination HIV drug sold by AbbVie <ABBV.N>, failed to improve outcomes for seriously ill COVID-19 patients.

(Reporting By Deena Beasley; Editing by Bill Berkrot)

Tags: Coronavirus Outbreak
Share196Tweet123
Reuters

Reuters

Reuters is an international news organization.

Advertisements

Top Stories June 10th
Top Stories June 7th
Top Stories June 6th
Top Stories June 3rd
Top Stories May 30th
Top Stories May 29th
Top Stories May 24th
Top Stories May 23rd
Top Stories May 21st
Top Stories May 17th

Join Over 6M Subscribers

We’re organizing an online community to elevate trusted voices on all sides so that you can be fully informed.





IJR

    Copyright © 2024 IJR

Trusted Voices On All Sides

  • About Us
  • GDPR Privacy Policy
  • Terms of Service
  • Editorial Standards & Corrections Policy
  • Subscribe to IJR

Follow Us

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Politics
  • US News
  • Commentary
  • World News
  • Faith
  • Latest Polls

    Copyright © 2024 IJR

Top Stories June 10th Top Stories June 7th Top Stories June 6th Top Stories June 3rd Top Stories May 30th Top Stories May 29th Top Stories May 24th Top Stories May 23rd Top Stories May 21st Top Stories May 17th